Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
PAPZIMEOS Q2 revenue more than doubled to $53.1 million, EPS of $0.05 beat an expected loss, and FDA exclusivity runs through 2032. Shares gained about 34% over 21 sessions, with $7.44 the near-term breakout level.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability Rebound ⢠Negative Cash Flow ⢠Elevated Leverage PGEN's strong quarterly profitability and liquidity improvement are offset by persistent cash burn, high leverage, dilution risk, and demanding valuation.
Price Behavior
Key Price Behavior Insights: ⢠Constructive uptrend ⢠Overbought momentum ⢠Resistance rejection Support Level: $7.42â$7.44; deeper support $6.85â$7.00 Resistance Level: $7.87 PGEN's constructive last-month uptrend remains intact above support, but near-overbought momentum and rejection near $7.87 favor caution unless it breaks higher.
Sentiment & News
Key News Insights: ⢠Revenue acceleration ⢠Quarterly profitability ⢠Pipeline advancement Precigen's PAPZIMEOS sales surge and quarterly profitability, supported by pipeline progress and rising investor interest, signal strengthening commercial momentum.
AI Summary
PGEN has shifted from a pipeline-only biotech to a PAPZIMEOS commercial execution story, but investors should require evidence that rapid launch revenue converts into sustained positive operating cash flow before underwriting its premium valuation; failure to do so could revive debt and dilution risk.
Description
Precigen, Inc. is a U.S.-based biotechnology company that discovers and develops gene and cell therapies and related disease-modifying therapeutics. The company also supports regenerative medicine and reproductive technologies, including genetically engineered swine and embryo transfer services, and maintains a suite of platform technologies for gene delivery, regulated expression, non-viral integration and microbial delivery of therapeutic proteins. Precigen has a history of collaboration and licensing arrangements with multiple partners, was founded in 1998, and changed its name from Intrexon Corporation in January 2020; it is headquartered in Germantown, Maryland.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 21 | Aug 28 | PGEN | Precigen, Inc. | PAPZIMEOS Q2 revenue more than doubled to $53.1 million, EPS of $0.05 beat an expected loss, and FDA exclusivity runs through 2032. Shares gained about 34% over 21 sessions, with $7.44 the near-term breakout level. | Closed | -3.5% |